The World Health Organization Short Disability Assessment Schedule: a validation study in patiens with schizophrenia by Mas-Expósito, Laia et al.
 1
The World Health Organization Short Disability Assessment 
Schedule (DAS-s): A validation study in patients with 
schizophrenia 
Authors: Laia Mas-Expósito,1,2 Juan Antonio Amador-Campos,2,3 Juana Gómez-
Benito,3,4 Lluís Lalucat-Jo1* for the Research Group on Severe Mental Disorder.5  
1. Department of Research, Centre d’Higiene Mental Les Corts, c/Numància 103-
105 baixos, 08029, Barcelona, Spain. Telephone number: 0034934198611. E-
mail: laia.mas@chmcorts.com 
2. Department of Personality, Assessment and Psychological Treatment, Faculty of 
Psychology, University of Barcelona, Passeig de la Vall d’Hebron 171, 08035, 
Barcelona, Spain. Telephone number: 0034933125131. E-mail: 
jamador@ub.edu 
3. Institute for Brain, Cognition and Behaviour, Barcelona, Spain. 
4. Department of Methodology, Faculty of Psychology, University of Barcelona, 
Barcelona, Passeig de la Vall d’Hebron 171, 08035, Barcelona, Spain. 
Telephone number: 0034933125082. E-mail: juanagomez@ub.edu. 
5. The Research Group on Severe Mental Disorder is composed of the following 
members from Adult Mental Health Care Centres in Barcelona: Mª Antonia 
Argany, Francesca Asensio, Marta Berruezo, Carlos Blecua, Ignasi Bros, Ana 
Isabel Cerrillo, Ana del Cuerpo, Amparo Escudero, Judit Farré, Clara Fort, 
Marisa García, Mª Carmen González, Eva Leno, Lluís Mauri, Isabel Mitjà, 
Mónica Montoro, Montserrat Nicolás, Rosa Ordoñez, Carmen Pinedo, 
Montserrat Prats, Mª Joaquina Redin, Mª Teresa Romero, Francesc Segarra, 
Juan Carlos Valdearcos, Immaculada Zafra, Matías Zamora and Antonio Zúñiga. 
 2
 
*Corresponding author. Department of Research, Centre d’Higiene Mental Les Corts, 
c/Numància 103-105 baixos, 08029, Barcelona, Spain. Tel.: +34-93.439.16.42. E-mail 
address: lluis.lalucat@chmcorts.com (L. Lalucat) 
Source of support: This study was supported by grant PI050789 from the Ministry of 
Health and Consumer Affairs of Spain, Carlos III Institute of Health, Health Research 
Fund, Madrid, Spain, and grant 2009SGR00822 from the Agency for Management of 
University and Research Grants, Government of Catalonia, Barcelona, Spain.  
Running head: Disability assessment in patients with schizophrenia 
Number of words in the manuscript: 4081 
Abstract word count: 255 
Number of tables: 4 









Purpose: The World Health Organization Short Disability Assessment Schedule 
(DAS-s) is used for patients with schizophrenia even though no validation is available. 
This paper addresses this issue by dealing with its psychometric properties in a clinical 
sample of patients with schizophrenia. 
Methods: Two hundred forty-one patients from 10 Adult Mental Health Care Centres 
(AMHCC) meeting the following inclusion criteria were included: 1) International 
Classification of Diseases-10 or ICD-10 diagnosis of schizophrenia; 2) Global 
Assessment of Functioning scores or GAF≤50;  3) Illness duration of more than 2 years; 
and 4) Clinical stability at assessment time. Patients were evaluated at baseline and at 
one-year follow-up regarding disability, socio-demographic and clinical variables, 
psychosocial measures and use of mental health services. 
Results: The factor analysis revealed a single factor that explained 60.57% of the 
variance. Internal consistency values were appropriate for the DAS-s total (0.78 at 
baseline and 0.78 at one year follow-up). Correlations between DAS-s scores and those 
of global functioning, psychiatric symptoms, social support and quality of life ranged 
between small and moderate (range: 0.13-0.39). There were significant differences 
between groups of patients with schizophrenia in the DAS-s. Patients who were 
unemployed, with lower global functioning, with cognitive impairment and lacking 
social support scored significantly lower in DAS-s scores. After one year follow-up, 
there was a non-significant decrease in DAS-s scores and patients improved 
significantly in overall functioning and psychiatric symptoms.  
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Discussion: This study shows that the DAS-s has good reliability and validity, and 














The World Health Organization Short Disability Assessment 
Schedule (DAS-s): A validation study in patients with 
schizophrenia 
1. Introduction 
Disability is seen in impairments on daily life activities involving, for example, personal 
care, occupation and family and social relationships. Disability is present in mental 
health disorders and, particularly, in persons suffering from schizophrenia who, due to 
disability, may show difficulties in having a major life activity.[1;2] Taking into 
account these consequences, it is justified that disability would be an essential element 
of investigation and practice in the context of rehabilitation in patients with 
schizophrenia.[3]  
The assessment of disability in rehabilitation is limited by the following factors[4]: 1) 
several measurement methods (i.e. self-report, hetero-report, performance based report, 
etc.), 2) ambiguity between disability and other related terms (i.e. functioning, living 
skills, incapacity, etc.) and 3) lack of agreement on the scope of its meaning. The World 
Health Organization developed the Short Disability Assessment Schedule or DAS-s[5] 
which is an instrument to assess disability in mental disorders that deals with the above 
mentioned limitations. It takes into account different sources of information and it 
provides a concise and cross-culturally agreed upon definition of disability based on the 
International Classification of Impairments, Disabilities and Handicaps.[6]   
The DAS-s[5] is derived from the World Health Organization Psychiatric Assessment 
Schedule or DAS[7] which is a semi-structured interview developed for the assessment 
of disability of patients with mental disorders and, specifically, psychotic patients. It 
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was developed in two international field trials of the multiaxial presentation of the 
International Classification of Diseases-10 or ICD-10[8] and assesses problems in 
personal care, occupational tasks and functioning with regard to the social setting of the 
patient. It can be used in different settings such as medical practice, research or audit 
and is an international disability evaluation tool applicable across different cultures.[5]  
Although no validation is available in patients with schizophrenia, the DAS-s has been 
used for the assessment of this patient population[9;10;11;12] because of its suitability, 
the aspects it covers and its psychometric properties with psychiatric patients.[5] This 
paper addresses the issue by validating this instrument in a clinical sample of 
outpatients with schizophrenia.  
Firstly, we aim to establish its factor structure. The results of the dimensionality of the 
test will guide the rest of psychometric analyses. Secondly, we address the internal 
consistency of this scale. Thirdly, we deal with its convergent validity. Namely, we 
study DAS-s associations with clinical and psychosocial variables and disability 
differences between groups of patients with schizophrenia, established according to 
socio-demographic variables, global functioning, psychiatric symptoms and social 
support. As observed in previous studies, we expect to find a positive relationship 
between disability and psychiatric symptoms [13;14;15;16;17]; while finding a negative 
one between disability and social support,[18] quality of life[19] and measures of global 
functioning. McKibbin et al. (2004)[4] found, in general terms, no associations between 
disability and socio-demographic variables, while Alpetkin et al. (2005)[17] only found 
significant associations between disability and employment. We do not expect there to 
be significant differences between groups of patients with schizophrenia based on socio-
demographic variables. Taking into account the above mentioned expected 
relationships, we expect to find disability differences between groups of patients with 
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schizophrenia, established according to global functioning, psychiatric symptoms and 
social support. Specifically, we expect to find that patients with higher global 
functioning, lower levels of psychiatric symptoms (i.e. depression, anxiety, insight and 
cognition) and higher social support will show lower levels of disability.  
Finally, we aim to test the capacity of the DAS-s to detect changes over time and to 
establish its sensitivity to change after one-year follow-up. We anticipate significant 
improvements in perceived social support, global functioning, psychiatric symptoms, 
disability and quality of life in relation to community treatment provided to patients[20]. 
2. Methods 
2.1. Sample 
Patients came from 10 Adult Mental Health Care Centres (AMHCC) in Barcelona 
(Spain). These AMHCC are run by the Catalan Department of Health and share similar 
characteristics regarding the care provided to patients. They offer a care package to 
patients with schizophrenia by means of multidisciplinary community mental health 
teams (i.e. a psychiatrist, a psychologist, a community mental health nurse and a social 
worker). This care package involves medical and psychosocial interventions of varying 
intensity depending on patients’ needs and is coordinated by one of the members of the 
mental health teams (i.e. a community mental health nurse).  
From December 2006 to January 2008, these AMHCC participated in a study consisting 
of a one-year follow-up of patients in contact with services who met the following 
inclusion criteria: 1) Global Assessment of Functioning or GAF[21] scores of 50 or 
lower, 2) Illness length greater than 2 years, 3) ICD-10[8] diagnosis of schizophrenia 
and 4) Clinical stability at assessment time. Patients were excluded if they had 
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dementia, organic brain injury or mental retardation. Patients who visited consecutively 
and who met study inclusion criteria were asked to participate. Specifically, 260 
patients met these inclusion criteria but 19 did not consent to participate. Data from this 
study was used in this paper. 
The final sample comprised 241 (67.6% male) patients, their mean age was 41.7 years 
(SD = 11.6) and 72.6% of them had illness duration greater than 10 years; 70.5% of 
patients had a diagnosis of paranoid schizophrenia and 29.5% of other schizophrenias 
(i.e. 10.8% undifferentiated, 9.1% residual, 6.2% hebephrenic, 1.2% simple and 2.1% 
other). Other socio-demographic characteristics of patients are described in Table 1.  
INSERT TABLE 1 HERE  
A total of 219 patients (90.9%) were successfully evaluated at one-year follow-up. 
Sixteen people (out of 22) were not evaluated following their psychiatrist’s instructions 
because they were not clinically stable at assessment time or did not have contact with 
services, 3 died (1 from terminal illness and 2 by suicide), 2 did not properly complete 
the evaluation and 1 dropped out of the study. 
2.2. Instruments 
Patients were evaluated at baseline and at one-year follow-up with the following 
assessment tools:  
The DAS-s.[5] It is a semi-structured interview based on the clinician’s assessment of 
the information obtained from the patient, caregivers, family, case notes and other 
records. It is derived from the DAS[7] and is composed of the following items[5]: 1) 
personal care, which refers to personal hygiene, dressing, feeding, etc.; 2) occupation, 
which refers to expected functioning in paid activities, studying, homemaking, etc.; 3) 
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family and household members, which refers to expected interaction with partner, 
parents, children, etc.; and 4) broader social context, which refers to expected 
performance in relation to community members, participation in social activities, etc. 
Each item is rated on a 6-point scale with the following anchor points: 0 = no disability 
at any time; 1 = deviation from the norms in the performance of one or more of the 
tasks or roles expected to be carried out by the patient in his or her cultural setting; 2 = 
deviation from the norms is conspicuous and dysfunction interfere with social 
adjustment (i.e. slightly disabled most of the time or moderately disabled some of the 
time); 3 = deviation from the norms in most of the expected tasks and roles; 4 = 
deviation from the norms in all of the expected tasks and roles; and 5 = deviation from 
the norms has reached a crisis point (i.e. the patient is severely disabled all of the time). 
The addition of all item scores provides an overall measure of disability.[9;11;12] The 
higher the score, the greater the disability perceived by the clinician. Besides the above 
mentioned items, there are also three other items not included in the scoring, but which 
the clinician needs to take into account when rating the DAS-s. First, time covered by 
the rating (i.e. current, last month, last year and other). Second, total duration of 
disability (i.e. less than one year, one year or more and unknown). Finally, specific 
abilities of the patient (i.e. presence and description). 
The DAS-s was developed in the framework of the multiaxial presentation of the ICD-
10.[5] It involved: 1) elaboration of a draft version by an international expert advisory 
group; 2) revision of the draft version by participants in the development of different 
versions of the ICD-10,[8] heads of WHO centres, the World Psychiatric Association, 
etc.; and 3) elaboration of the final version of the DAS-s based on the DAS.[7] During 
its development[5] the DAS-s showed good psychometric properties. The DAS-s 
intraclass correlation coefficients ranged from 0.40 for disability in family and 
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household activities to 0.74 for disability in personal care. Moreover, 50% of specific 
disability categories had kappa values higher than 0.50.  
In this study the time covered in the rating was the last month. 
The GAF.[21] This is a reliable and valid measure of global psychological functioning 
in patients with severe mental disorder. Its theoretical range is 1-100, where 100 denotes 
best possible functioning. It is included in the Diagnostic and Statistical Manual of 
Mental Disorders Fourth Edition [21] or DSM-IV. 
The Positive and Negative Syndrome Scale[22] or PANSS. This instrument is used for 
assessing symptom severity in patients with schizophrenia and it has been translated 
into and is validated in Spanish.[23] It assesses psychiatric symptoms in three domains: 
positive (theoretical range: 7-49 where 49 denotes higher levels of positive psychiatric 
symptoms), negative (theoretical range: 7-49 where 49 represents higher levels of 
negative psychiatric symptoms), general (theoretical range: 16-112; where 112 denotes 
higher levels of general psychiatric symptoms), and provides an overall measure of 
psychiatric symptoms (theoretical range: 30-210, where 210 means higher levels of 
psychiatric symptoms). Internal consistency values of its subscales range between 
medium and high and its convergent validity with other measures of psychiatric 
symptoms is high and ranges from 0.70 to 0.81.[23] 
The Functional Social Support Questionnaire[24] or FSSQ. This is an eleven-item 
questionnaire that measures the strength of the patient’s social network. It assesses 
perceived social support in two domains: confidential social support (theoretical range: 
6-30, where 30 denotes higher levels of confidential social support) and affective social 
support (theoretical range: 5-25, where 25 represents higher levels of affective social 
support), and provides an overall measure of social support (theoretical range: 11-55, 
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where 55 shows higher levels of social support). It has also been translated into and 
validated in Spanish[25] and the reliability indexes are 0.80 and 0.92 for hetero-report 
and self-report, respectively. The concurrent validity with other health measures ranges 
in absolute values from 0.13 to 0.81.[25] 
The World Health Organization Quality of Life Scale Brief Version [26] or WHOQOL-
BREF. It is a short version of the World Health Organization Quality of Life Scale or 
WHOQOL-100, which is considered an international, cross-culturally analogous quality 
of life evaluation tool.[27] During its development, internal consistency values ranged 
from 0.66 to 0.84; and correlations with the WHOQOL-100 subscales ranged from 0.89 
to 0.95.[27] Skevington et al. (2004)[28] confirmed and extended information about its 
properties and showed good to excellent psychometric properties. There is a Spanish 
version[29] that shows good psychometric properties in patients with schizophrenia.[30] 
2.3. Procedure 
The study was approved by the Ethics Committee of the Catalan Union of Hospitals in 
accordance with the ethical standards of the 1964 Declaration of Helsinki. The 
procedures and assessments were described to each patient who then provided informed 
consent.  
The community mental health teams performed patient assessments. The diagnosis was 
established by the psychiatrist by means of a non-structured interview following ICD-
10[8] research diagnosis criteria and considered self-reports and caregiver reports. The 
psychiatrist also carried out the assessment of psychiatric symptoms, while the rest of 
the assessments were performed by the other members of the community mental health 
teams under the psychiatrist’s supervision. The psychiatrist was in charge of setting up 
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the assessment agenda, supervising its development and sending the score sheets to the 
psychologist in charge of the design and analyses of the study database. 
To ensure the quality of data assessment, all psychiatrists participated in a schizophrenia 
diagnostic agreement workshop comprising two case vignettes. All researchers were 
trained in the administration of the instruments in a 4-hour session run by a psychologist 
with experience in psychological assessment of psychiatric patients. Systematic reviews 
of data coding and registration were taken and patient information was contrasted with 
data from the AMHCC responsible for each patient. 
First, the psychiatrist conducted the assessment of global functioning and psychiatric 
symptoms with the GAF and the PANSS to check if patients met inclusion criteria. 
Then, the other members of the community mental health teams administered the rest of 
assessment tools in the following order: 1) DAS-s, 2) the WHOQOL-BREF and 3) the 
FSSQ.  
After each evaluation, systematic reviews of data coding and registration were taken 
and patient information was contrasted with family interviews and AMHCC registered 
data. 
2.4. Data analysis 
Exploratory factor analysis (EFA) was performed using principal axis factoring. Factors 
were selected taking into account the following criteria: eigenvalues > 1, the coefficient 
between the variance explained for the first factor and the second one, and the analysis 
of the scree plot.[31;32] 
Internal consistency was evaluated by means of Cronbach’s α and the contribution of 
DAS-s items to the overall α. The internal consistency was calculated at baseline and at 
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one-year follow-up. Cronbach’s α values were considered as follows: 0.60≤ α <0.80 
adequate, 0.80≤ α <0.85 good and α ≥0.85 excellent.[33] 
To assess convergent validity,[34] Pearson’s correlations between DAS-s scores at 
baseline and the GAF, PANSS, FSSQ and WHOQOL-BREF scores at baseline were 
calculated. Correlation values were considered as follows: 1) <0.3 = small, 2) 0.3 to 
0.5 = moderate and 3) ≥5 large.[35] T-tests and analysis of variance were used to 
analyze differences in DAS-s scores between groups of patients with schizophrenia. 
Patient groups were defined according to socio-demographic variables, low global 
functioning[21] (GAF scores ≤ 50), the presence of anxiety symptoms[22] (item 2 of 
PANSS general ≥4), depressive symptoms[22] (item 6 of PANSS general ≥4), lack of 
insight[22] (item 12 of PANSS general ≥4), cognitive impairment[22] (item 5 of 
PANSS negative ≥4) and lack of social support[25] (FSSQ ≤32). 
T-tests for dependent samples were used to assess change over time between baseline 
and at one-year follow-up for DAS-s, GAF, PANSS, FSSQ and WHOQOL-BREF 
scores and AMHCC visits. The Bonferroni correction for multiple comparisons was 
applied[35] and a p value ≤0.003 was considered significant. The effect size was also 
estimated[36] and its values were considered as follows: 1) <0.3=small, 2) 0.3 to 
0.5=moderate and 3) ≥5 large.[37] 
Differences between scores at baseline and at one-year follow-up were calculated for 
DAS-s scores, GAF, PANSS, FSSQ, WHOQOL-BREF scores and AMHCC visits. 
Sensitivity to change was determined by Pearson’s correlation coefficients between 
DAS-s score differences and the other score differences. 
Data were analysed using the Statistical Package for the Social Sciences v.15.  
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3. Results 
3.1. Factor Analysis 
The analysis of the correlation and anti-image matrices, and the results of the Kaiser-
Meyer-Olkin measure of sampling adequacy (K-M-O=0.77; Barlett's Test of Sphericity: 
Chi-square=264.58, df=6, p<0.0001) showed that DAS-s data was appropriate to run the 
factor analysis. The EFA revealed a one-factor structure with an eigenvalue of 2.42, 
which explained 60.57% of the variance. Loadings of items from 1 to 4 were: 0.71, 
0.80, 0.84 and 0.76, respectively.  
3.2. Internal consistency 
Internal consistency coefficients for DAS-s were 0.78 at baseline and 0.78 at one year 
follow-up. We also tested the change in Cronbach's alpha values when items are 
suppressed. The suppression of any of the items decreased internal consistency 
coefficients at baseline and at one-year follow-up (range: 0.01-0.09). Item suppression 
decreased Cronbach's alpha values by 0.09 as maximum, which may be considered 
negligible. 
3.3. Convergent validity 
Pearson's correlations between DAS-s scores and GAF, PANSS, FSSQ and WHOQOL-
BREF scores at baseline were mostly significant, and ranged from 0.13 to 0.39 in 
absolute values (see Table 2). Specifically, correlations between DAS-s and GAF scores 
were negative and mainly small; correlations between DAS-s and PANSS scores were 
positive and ranged between small and moderate; correlations between DAS-s scores 
and FSSQ were negative and ranged between small and moderate, and correlations 
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between DAS-s and WHOQOL-BREF scores were negative and ranged between small 
and moderate. 
Table 2 shows the differences in DAS-s scores for groups of patients with 
schizophrenia. There were no statistically significant differences in DAS-s scores 
between groups established according to socio-demographic variables except for 
employment status. Namely, active patients scored significantly lower than non-active 
patients in all DAS-s scores [DAS-s personal care: t(101.06) = –3.082 (p=0.003); DAS-
s occupation: t(239) = –6.575 (p<0.001); DAS-s family and household: t(104.79) = –
3.623 (p<0.001); DAS-s broader social context: t(239) = –3.427 (p=0.001); DAS-s total: 
t(239) = –5.220 (p<0.001)]. There were significant differences in DAS-s scores between 
groups of patients with schizophrenia established according to clinical functioning, 
social functioning, cognitive impairment and social support.  In particular, patients with 
higher clinical functioning, higher social functioning, without cognitive impairment and 
higher social support scored significantly lower in almost all DAS-s scores. 
INSERT TABLE 2 HERE 
3.4. Changes over time 
As shown in Table 3, DAS-s scores decreased over time, but not significantly. There 
were statistically significant changes over time regarding PANSS positive, PANSS 
negative, PANSS general, PANSS total, GAF clinical and GAF social scores. To be 
precise, there was a decrease in psychiatric symptoms as shown by changes in PANSS 
scores over time and an improvement in overall functioning as indicated by changes in 
GAF scores over time. Effect sizes were medium for most scores but small for GAF 
social scores. FSSQ scores and WHOQOL-BREF scores remained about the same over 
time. With regard to AMHCC visits, there were statistically significant changes over 
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time in nursing visits. Specifically, there was an increase in nursing visits with a small 
effect size. No other statistically significant differences over time were observed (See 
Table 3). 
INSERT TABLE 3 HERE  
3.5. Sensitivity to change 
Firstly, score differences between baseline and one-year follow-up were calculated for 
DAS-s scores, the other assessment tools and AMHCC visits. Secondly, Pearson's 
correlation coefficients between DAS-s score differences and all other score differences 
were calculated. Table 4 shows that Pearson's correlations between changes in DAS-s 
scores and changes in GAF, PANSS, FSSQ, WHOQOL-BREF scores were mostly 
significant. Those coefficients ranged from 0.00 to 0.33 in absolute values. In particular, 
correlations between the change in DAS-s and the change in GAF scores were negative 
and ranged between small and moderate; correlations between changes in DAS-s and 
changes in PANSS scores were positive and small; correlations between changes in 
DAS-s and changes in FSSQ scores were negative and small; correlations between 
changes in DAS-s and changes in WHOQOL-BREF scores were mainly negative and 
small. As for AMHCC visits, there were no statistically significant correlations.  
INSERT TABLE 4 HERE  
4. Discussion  
The aim of this study was to validate the DAS-s in patients with schizophrenia. The 
DAS-s showed suitable psychometric properties in this patient population. 
The factor analysis revealed a single factor that explained a high percentage of 
variability. This supports the use of an overall measure as a sum of the 4 items of the 
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DAS-s.[9;11;12] Janca (1996)[5] suggested that the DAS-s items be scored individually 
taking into account a clinical criteria but not the factor structure of the scale. To our 
knowledge this is the first study that aims to establish its factor structure. 
Internal consistency values at baseline and at one-year follow-up were adequate for the 
DAS-s total. During the development of the DAS-s,[5] the study of its psychometric 
properties was conducted using case vignettes and a sample of psychiatric patients 
recruited consecutively, and included content analyses and assessments of inter-rater 
reliability. The authors concluded that the DAS-s was useful, user-friendly and reliable. 
Our findings are an extension regarding the adequacy of the psychometric properties of 
the DAS-s.  
We expected to find a positive relationship between disability and psychiatric 
symptoms[13;14;15;16;17]; while finding a negative one between disability and social 
support[18], quality of life[19] and global functioning. Those were the directional 
relationships of our findings, which have been found in other studies. Findings 
regarding the relationship between disability and psychiatric symptoms are 
controversial. Most authors show that there is a significant and positive relationship 
between disability and psychiatric symptoms, although some of them show that 
disability is associated only with negative symptoms,[13;16;15] some with both 
negative and positive symptoms[14] and others with psychiatric symptoms in general 
terms.[17] Our findings are consistent with the association between disability and 
psychiatric symptoms in general terms.  
As observed in other studies,[4] we found significant and negative associations between 
disability, functioning and quality of life. In our study, we used the GAF for the 
assessment of functioning and the WHOQOL-BREF for quality of life. They both aim 
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to measure the functioning of persons in their own environment. This may explain why 
they show the greatest correlation coefficients with disability. With regard to perceived 
social support, the present study showed that perceived social support is related to 
community adaptation in the sense that the higher the social support perceived, the 
better the community adaptation.[38] One should think that the DAS-s is intended to 
measure patient adaptation in its own environment or, in other words, community 
adaptation. It is worth noting that disability and functioning were clinician-rated (DAS-s 
and GAF) while social support and quality of life were self-rated (FSSQ and 
WHOQOL-BREF). The fact that the raters are different may explain why the 
correlation coefficients of the latter variables were not as great as one would expect.[39]   
There were no differences in DAS-s scores between groups of patients established 
according to socio-demographic variables, except for employment. Our findings have 
been observed in other studies. For instance, McKibbin et al. (2004)[4] found no 
association between socio-demographic characteristics (i.e. age, education, gender and 
ethnicity) and overall disability scores. When examining disability domains, McKibbin 
et al. (2004)[4] found some associations between disability and socio-demographic 
variables in a sample of older patients with schizophrenia. Our results are, in general 
terms, congruent with the above mentioned results, but we did not find associations 
between disability domains and socio-demographic variables. This could be related to 
the use of different tools to assess disability and to the specific characteristics of the 
samples included. For example, the mean age in the present study was lower than that in 
the research by McKibbin et al. (2004)[4]. Our results are also congruent with the 
results of Alpetkin et al. (2005)[17] which show no significant associations between 
disability and age, gender and marital status, but a significant association between 
disability and employment. Further research may involve the effects of 
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employment/occupational programmes in this sample population, which seem to lessen 
disability[40] and, also, extend the information about the relationship between disability 
and socio-demographic variables since other studies have found differences between 
DAS-s scores and socio-demographic variables such as gender.[9]  
There were significant differences between patient groups. As expected, patients with 
lower functioning, cognitive impairment and lacking social support showed higher 
disability levels in almost all DAS-s scores. The findings about functioning and social 
support are congruent with the relationship stated for these variables with disability 
earlier in the discussion. As for cognitive impairment, our findings support a body of 
evidence that show a relationship between cognitive impairment and 
disability.[41;42;43] Although we also hypothesised disability differences between 
groups of patients established according to levels of depression,[4; 17] anxiety[44] and 
insight impairment,[45;46;47] our study did not find such associations. Even so, one 
should note that group differences may be unreliable since they were made according to 
established cut-offs of single scale items rather than through diagnostic interviews. 
Further research is needed to clarify the relationship between psychiatric symptoms and 
disability since, as already mentioned, it is controversial. 
At one-year follow-up after the provision of care to patients through AMHCC,[20] we 
expected a decrease in disability and psychiatric symptoms and an in increase in levels 
of general functioning, social support and quality of life. There were only improvements 
regarding psychiatric symptoms and global functioning together with an increase of 
community psychiatric nursing visits. We did not observe significant improvements 
regarding disability, social support or quality of life. This might somehow reflect the 
need for more specific psychosocial interventions aimed to improve disability, social 
support and quality of life.[48] The lack of changes in DAS-s scores at one year follow-
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up might be one of the reasons why there are only small significant associations 
between changes in DAS-s scores between baseline and one year follow-up and changes 
in the rest of tests scores and AMHCC visits between baseline and one year follow-up. 
To date, the DAS-s has been used for the assessment of patients with schizophrenia 
even though no validation of the scale is available. This paper provides evidence 
regarding the psychometric properties of the DAS-s in patients with schizophrenia. The 
DAS-s has good reliability and validity, which supports its use in this patient 
population. Taking all the above into account, it can be considered that the DAS-s could 
be used for the assessment of disability in patients with schizophrenia as an evaluation 
tool for purposes such as research or routine practice. Future research should involve 
psychometric properties in other sample populations, such as other mental disorders as 
well as other populations with disability.  
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Table 1. Socio-demographic characteristics of the sample at baseline 
 
Variable N % 
Age Mean(SD) 41.71(11.60)  
Gender   
  Female 78 32.4 
  Male 163 67.6 
Illness duration   
   < 5 years 24 10.0 
   From 5 to 10 years 42 17.4 
   > 10 years 175 72.6 
Marital status   
  Single 181 75.1 
  Living with partner or married 32 13.3 
  Divorced, separated or widowed 28 11.6 
Educational level   
   ≤ Primary school 113 46.9 
   > Primary school 128 53.1 
Living arrangement   
   Family property 166 68.9 
   Other 45 31.1 
Employment status   
   Active 53 22 
   Non-active 188 78 
Schizophrenia type   
  Paranoid 170 70.5 
  Other 71 29.5 
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Association with clinical and psychosocial variables: 
 (n=241) [r (p value)]  
     
GAF2-clinical –0.264 (p<0.001) –0.306 (p<0.001) –0.295 (p<0.001) –0.308 (p<0.001) –0.377 (p<0.001) 
GAF-social –0.217 (p<0.001) –0.323 (p<0.001) –0.320 (p<0.001) –0.351 (p<0.001)  –0.390 (p<0.001) 
PANSS3 positive 0.223 (p<0.001) 0.128 (p=0.047) 0.290 (p<0.001) 0.166 (p=0.010) 0.259 (p<0.001) 
PANSS negative 0.169 (p=0.008) 0.260 (p<0.001) 0.204 (p=0.010) 0.341 (p<0.001) 0.312 (p<0.001) 
PANSS general 0.166 (p=0.010) 0.155 (p=0.060) 0.236 (p<0.001)  0.252 (p<0.001) 0.259 (p<0.001) 
PANSS total 0.209 (p=0.001) 0.204 (p=0.001) 0.278 (p<0.001)  0.295 (p<0.001) 0.316 (p<0.001) 
FSSQ4-total social support –0.308 (p<0.001) –0.223 (p<0.001) –0.340 (p<0.001) –0.264 (p<0.001) –0.364 (p<0.001) 
FSSQ-confidential support –0.261 (p<0.001) –0.184 (p=0.004) –0.299 (p<0.001) –0.270 (p<0.001) –0.324 (p<0.001) 
FSSQ-affective support –0.295 (p<0.001) –0.193 (p<0.001) –0.307 (p<0.001) –0.179 (p<0.001) –0.313 (p<0.001) 
WHOQOL-BREF5 physical –0.231 (p<0.001) –0.267 (p<0.001) –0.149 (p=0.021)  –0.303 (p<0.001) –0.304 (p<0.001) 
WHOQQOL-BREF psychological –0.231 (p<0.001) –0.202 (p<0.001) –0.216 (p=0.001) –0.330 (p<0.001) –0.312 (p<0.001) 
WHOQQOL-BREF social relations –0.221 (p=0.001)   –0.186 (p=0.004) –0.249 (p<0.001) –0.307 (p<0.001) –0.307 (p<0.001) 
WHOQQOL-BREF environment –0.261 (p=0.001) –0.253 (p=0.001) –0.277 (p=0.001) –0.321 (p=0.001) –0.356 (p=0.001) 
WHOQQOL-BREF total –0.295 (p<0.001) –0.288 (p<0.001) –0.274 (p<0.001) –0.388 (p<0.001) –0.398 (p<0.001) 
Group differences: (n=241) [t test(p value)]       
Low clinical functioning vs. high clinical functioning  4.062 (p<0.001)  4.079 (p<0.001) 3.455 (p<0.001) 3.929 (p<0.001) 4.963 (p<0.001) 
Low social functioning vs. high social functioning 2.802 (p=0.006) 4.718 (p<0.001) 3.788 (p<0.001) 4.320 (p<0.001) 5.018 (p<0.001) 
Depressed vs. non depressed  –0.117 (p=0.907) –0.537 (p=0.591) –0.600 (p=0.549) –2.282 (p=0.023) –1.106 (p=0.270) 
Anxious vs. non anxious  0.109 (p=0.913) 0.811(p=0.420) 1.058(p=0.291) 1.231(p=0.222) 1.049 (p=0.362) 
Insight impairment vs. non insight impairment  –1.485 (p=0.139) –2.761 (p=0.006) –2.216 (p=0.028) –2.564 (p=0.011) –2.931 (p=0.004) 
Cognitive impairment vs. non cognitive impairment –1.840 (p=0.067) –3.055 (p=0.003) –1.495 (p=0.136) –3.473 (p=0.001) –3.192 (p=0.002) 
Lacking social support vs. having social support –4.127 (p<0.001) –3.410 (p=0.001) –4.355 (p<0.001) –3.633 (p<0.001) –5.010 (p<0.001) 
n= simple size at baseline 
1. DAS-s: The World Health Organization Short Disability Assessment Schedule; 2. GAF: Global Assessment of Functioning;  3. PANSS: Positive and Negative Syndrome Scale;  4. FSSQ: 




Table 3. Clinical and psychosocial variables and use of health services at baseline and at one year follow-up 
 
Measure Baseline 1 year follow-up Differences over time 
 Mean SD Mean SD t p ES 
(n=219)        
DAS-s1 personal care 1.32 1.35 1.18 1.26 2.18 0.031 0.15 
DAS-s occupation 2.72 1.54 2.59 1.58 –1.37 0.172 0.09 
DAS-s family and household 2.05 1.48 2.01 1.45 0.56 0.579 0.04 
DAS-s broader social context 3.00 1.37 2.81 1.45 –2.26 0.025 0.15 
DAS-s total 9.09 4.46 8.59 4.46 2.37 0.018 0.16 
PANSS2 positive 16.67 6.26 15.22 6.10 5.02 <0.001 0.32 
PANSS  negative 24.07 6.99 22.34 6.90 5.08 <0.001 0.33 
PANSS  general 42.35 12.73 39.22 12.30 5.30 <0.001 0.34 
PANSS  total 83.10 22.47 76.79 21.96 6.14 <0.001 0.38 
GAF3 clinic 47.07 9.69 49.58 11.01 –4.94 <0.001 0.32 
GAF social 44.29 10.00 46.26 10.36 –3.45 <0.001 0.23 
FSSQ4 confidant support 16.55 4.99 16.37 5.17 0.63 0.531 0.00 
FSSQ affective support 10.90 3.14 10.78 3.22 0.68 0.500 0.00 
FSSQ total social support 36.68 9.47 36.57 9.72 0.22 0.823 0.02 
WHOQOL-BREF5 physical health 13.25 2.42 13.27 2.54 –0.95 0.924 0.01 
WHOQOL-BREF psychological health 12.18 2.86 12.19 2.81 –0.01 0.990 0.00 
WHOQOL-BREF social relationships 10.54 3.26 10.50 3.24 0.23 0.816 0.02 
WHOQOL-BREF environment 13.24 2.26 13.31 2.36 –0.51 0.612 0.04 
WHOQOL-BREF general 81.82 13.94 81.95 14.11 –0.18 0.856 0.01 
AMHCC6 psychiatric visitsϒ 5.76 4.22 6.28 4.43 –1.75 0.082 0.12 
AMHCC nursing visitsϒ 5.92 7.13 8.38 9.03 –4.35 <0.001 0.28 
 
1.  DAS-s: The World Health Organization Short Disability Assessment Schedule; 2. PANSS: Positive and Negative Syndrome Scale; 3. GAF: Global Assessment of Functioning; 4. 
FSSQ: Functional Social Support Questionnaire; 5. WHOQOL-BREF: World Health Organization Quality of Life Scale Brief Version; 6. AMHCC: Adult Mental Health Care Centre 
 
SD: standard deviation; ϒ: Time frame= patient visits during the year prior to the first assessment versus patient visits during the year after the first assessment 
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Sensitivity to change (n= 219) 
[r (p value)] 
     
GAF2 clinical –0.18 (p=0.008) –0.09 (p=0.202) –0.27 (p<0.001) –0.15 (p<0.001) –0.25 (p<0.001) 
GAF social    –0.18 (p=0.009) –0.10 (p=0.048)  –0.29 (p<0.001) –0.28 (p<0.001) –0.33 (p<0.001) 
PANSS3 positive 0.21 (p=0.002) 0.03 (p=0.702) 0.21 (p=0.002) 0.13 (p=0.050) 0.20 (p=0.003) 
PANSS negative 0.13 (p=0.500) –0.00 (p=0.989) 0.17 (p=0.012) 0.18 (p=0.006) 0.17 (p=0.010) 
PANSS general 0.17 (p=0.012) –0.09 (p=0.200) 0.15 (p=0.024) 0.15 (p=0.029) 0.13 (p=0.062)  
PANSS total 0.20 (p=0.003) –0.04 (p=0.527) 0.20 (p=0.003) 0.18 (p=0.007) 0.19 (p=0.006) 
FSSQ4 total social support –0.06 (p=0.365) –0.02 (p=0.736) –0.16 (p=0.018) –0.20 (p=0.002) –0.17 (p=0.015) 
FSSQ confidential support –0.02 (p=0.766) –0.02 (p=0.778) –0.17 (p=0.010) –0.19 (p=0.005) –0.13 (p=0.050) 
FSSQ affective support –0.07 (p=0.297) –0.08 (p=0.226) –0.11 (p=0.100) –0.13 (p=0.056) –0.15 (p=0.028) 
WHOQOL-BREF5 physical –0.12 (p=0.082) –0.03 (p=0.710) –0.19 (p=0.004) –0.14 (p=0.043) –015 (p=0.030) 
WHOQOL-BREF psychological –0.16 (p=0.019) 0.00 (p=0.949) –0.18 (p=0.009) –0.19 (p=0.004) –0.19 (p=0.006) 
WHOQOL-BREF social relation 0.05 (p=0.442) –0.07 (p=0.291) –0.27 (p<0.001) –0.13 (p=0.065) –0.16 (p=0.020) 
WHOQOL-BREF environment 0.01 (p=0.907) –0.02 (p=0.796) –0.09 (p=0.175) –0.18 (p=0.007) –0.11 (p=0.112) 
WHOQOL-BREF total –0.10 (p=0.150) –0.02 (p=0.791) –0.23 (p=0.001) –0.24 (p<0.001) –0.21 (p=0.001) 
AMHCC6 psychiatric visitsϒ 0.11 (p=0.099) 0.02 (p=0.778) 0.13 (p=0.065) –0.04 (p=0.579) 0.07 (p=0.277) 
AMHCC nursing visitsϒ 0.00 (p=0.950) –0.06 (p=0.395) –0.08 (p=0.273)  –0.07 (p=0.341) –0.08 (p=0.266) 
n = sample size  
1. DAS-s: The World Health Organization Short Disability Assessment Schedule; 2. GAF: Global Assessment of Functioning; 3. PANSS: Positive and Negative Syndrome Scale; 4. FSSQ: 
Functional Social Support Questionnaire; 5. WHOQOL-BREF: World Health Organization Quality of Life Scale Brief Version; 6. AMHCC: Adult Mental Health Care Centre 
ϒ: Time frame= patient visits during the year prior to the first assessment versus patients visits during the year after the first assessment 
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